Clinical Trial

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Study acronym: MARITIME-OSA-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
Protocol Amendment History 6 changes
notable Trial sites expanded: 49 -> 53 locations 2026-06-05
notable Trial sites expanded: 46 -> 49 locations 2026-05-23
notable Trial sites expanded: 42 -> 46 locations 2026-05-15
notable Trial sites expanded: 38 -> 42 locations 2026-05-06
notable Trial sites expanded: 34 -> 38 locations 2026-04-25
notable Trial sites expanded: 28 -> 32 locations 2026-04-10
Trial Details
NCT Number NCT07226765
Lead Sponsor Amgen
Conditions Obstructive Sleep Apnea
Enrollment 250 participants
Start Date 2025-11-25
Primary Completion 2027-09-29 (estimated)
Study Completion 2028-09-13 (estimated)
Updated on ClinicalTrials.gov 2026-06-12